GPMP Notes in Narrative Format

GP MANAGEMENT PLAN - Type 2 Diabetes The patient's details were recorded, including their full legal name John Smith, date of birth 15/06/1965, and Medicare number 1234 5678 9101. Additionally, whether the patient identifies as Aboriginal or Torres Strait Islander was noted No. The patient's address 123 Main Street, Sydney, NSW, 2000, home phone number (02) 1234 5678, and mobile phone number 0412 345 678 were also recorded, as specified in the clinical notes. The date the GP Management Plan (GPMP) was completed 01/11/2024 was entered, alongside the date of any prior GPMP 01/05/2023. Details of the patient's usual GP were also noted, including their full name Dr. Emily Brown, qualifications MBBS, FRACGP, and the address of their practice 456 Health Avenue, Sydney, NSW, 2000. The phone number (02) 8765 4321 and fax number (02) 8765 4322 of the GP’s practice were recorded as applicable. In the assessment section, the patient's primary diagnosis or condition being managed was identified Type 2 Diabetes. The date of diagnosis was provided if available 01/01/2010. The patient's medical and surgical history was also detailed, focusing on any chronic conditions, past surgeries, hospitalizations, or treatments that might be relevant to the current condition. John has a history of hypertension and hyperlipidemia, and underwent appendectomy in 2005. A thorough list of the medications the patient was taking was included, noting the names of the medications, their dosages, and the frequency with which they were administered. Metformin 500mg twice daily, Lisinopril 10mg once daily, Atorvastatin 20mg once daily. The patient's known allergies were also recorded, including whether they were related to medications, foods, or other substances. No known allergies. The patient's immunisation history was reviewed, including any relevant vaccinations and the dates of the most recent vaccines. Up-to-date with influenza and pneumococcal vaccines, last received on 01/09/2024. The patient's smoking history was documented, with details on whether they smoked, the number of pack-years if applicable, or whether they had never smoked. Never smoked. A planned review date for the GPMP was set, typically at least six months after its completion date 01/05/2025. It was confirmed whether the GPMP had been added to the patient’s records Yes, and a copy of the GPMP was offered to the patient for their records Yes. For patient understanding and agreement, the statement "I understand the Management Plan recommendations and agree to the outlined goals" was included, followed by the patient’s signature if available John Smith and the date they signed the GPMP 01/11/2024. The GP’s signature or digital confirmation was also noted, with the date the GP signed or confirmed the plan Dr. Emily Brown, 01/11/2024. The patient’s current health needs or problems were described, focusing on the condition being managed. These included symptom management, risk factor modifications, or treatment adherence. The goal for managing the condition was specified, ensuring that it was measurable and specific, such as reducing symptoms, preventing exacerbations, improving quality of life, or meeting clinical targets. The primary goal is to maintain HbA1c below 7% and manage blood pressure within target range. The agreed actions between the health professionals and the patient were documented in relation to general, lifestyle, biochemical, medication, complications, and mental health support. The patient's understanding of their condition and the management plan was ensured through patient education provided during consultations, with follow-up discussions scheduled as necessary. Lifestyle factors were addressed, including quality of life, nutrition, physical activity, smoking cessation, and energy conservation. A balanced diet plan was provided, and a walking regimen of 30 minutes daily was recommended. Biochemical aspects were also addressed, including spirometry or other relevant tests to monitor disease progression. The frequency of assessments, such as spirometry, was planned, along with key measurements such as FEV1/FVC ratios. Regular blood glucose monitoring and quarterly HbA1c tests were scheduled. The medication review was scheduled to ensure that the patient understood their medications and the proper use of inhalers or other prescribed treatments. Immunisation status was also confirmed, and any necessary vaccinations were planned. The management plan also included monitoring for potential complications, such as assessing the patient's overall health and managing any risks associated with treatments or the condition. Necessary tests were scheduled, and guidance was provided to help the patient maintain their overall health through diet, exercise, and lifestyle modifications. The patient's mental health and wellbeing were considered, with appropriate assessments for depression, anxiety, or stress. If necessary, referrals for mental health support, such as therapy or counseling, were offered. Finally, social support and isolation were addressed, with encouragement for the patient to participate in social support networks to reduce isolation and improve emotional wellbeing.